IRIS Accounts Production v25.1.4.42 05084053 Board of Directors 1.1.24 31.12.24 31.12.24 true false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh050840532023-12-31050840532024-12-31050840532024-01-012024-12-31050840532022-12-31050840532023-01-012023-12-31050840532023-12-3105084053ns15:EnglandWales2024-01-012024-12-3105084053ns14:PoundSterling2024-01-012024-12-3105084053ns10:Director12024-01-012024-12-3105084053ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3105084053ns10:SmallEntities2024-01-012024-12-3105084053ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3105084053ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3105084053ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3105084053ns10:AbridgedAccounts2024-01-012024-12-3105084053ns10:Director22024-01-012024-12-3105084053ns10:Director32024-01-012024-12-3105084053ns10:CompanySecretary12024-01-012024-12-3105084053ns10:RegisteredOffice2024-01-012024-12-3105084053ns5:CurrentFinancialInstruments2024-12-3105084053ns5:CurrentFinancialInstruments2023-12-3105084053ns5:Non-currentFinancialInstruments2024-12-3105084053ns5:Non-currentFinancialInstruments2023-12-3105084053ns5:ShareCapital2024-12-3105084053ns5:ShareCapital2023-12-3105084053ns5:RetainedEarningsAccumulatedLosses2024-12-3105084053ns5:RetainedEarningsAccumulatedLosses2023-12-3105084053ns5:WithinOneYear2024-12-3105084053ns5:WithinOneYear2023-12-3105084053ns5:BetweenOneFiveYears2024-12-3105084053ns5:BetweenOneFiveYears2023-12-3105084053ns5:MoreThanFiveYears2024-12-3105084053ns5:MoreThanFiveYears2023-12-3105084053ns5:AllPeriods2024-12-3105084053ns5:AllPeriods2023-12-3105084053ns5:Secured2024-12-3105084053ns5:Secured2023-12-31
REGISTERED NUMBER: 05084053 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

MEDSA GROUP LIMITED

MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

CONTENTS OF THE FINANCIAL STATEMENTS
For The Year Ended 31 December 2024










Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 4


MEDSA GROUP LIMITED

COMPANY INFORMATION
For The Year Ended 31 December 2024







DIRECTORS: J R Salvage
J M Lee
D N Sharpe





SECRETARY: J R Salvage





REGISTERED OFFICE: Sandy Farm
The Sands
Farnham
Surrey
GU10 1PX





REGISTERED NUMBER: 05084053 (England and Wales)

MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

ABRIDGED BALANCE SHEET
31 December 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 5,173 6,900
Investments 5 3,397,832 3,280,758
3,403,005 3,287,658

CURRENT ASSETS
Stocks 338,603 269,930
Debtors 2,518,224 2,757,444
Cash in hand 16 31
2,856,843 3,027,405
CREDITORS
Amounts falling due within one year 256,663 265,405
NET CURRENT ASSETS 2,600,180 2,762,000
TOTAL ASSETS LESS CURRENT
LIABILITIES

6,003,185

6,049,658

CREDITORS
Amounts falling due after more than one year 5,754,857 5,843,000
NET ASSETS 248,328 206,658

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 248,228 206,558
SHAREHOLDERS' FUNDS 248,328 206,658

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

ABRIDGED BALANCE SHEET - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 31 December 2024 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 June 2025 and were signed on its behalf by:





D N Sharpe - Director


MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

NOTES TO THE FINANCIAL STATEMENTS
For The Year Ended 31 December 2024


1. STATUTORY INFORMATION

Medsa Group Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover represents the sale of corporate solutions products and services, excluding value added tax, during the year.

Turnover is recognised as the right to consideration arises and adjustments are made for accrued and deferred income.

Tangible fixed assets
Tangible fixed assets are stated at cost or valuation less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended by management.

Depreciation is provided at the following annual rates in order to write off each asset its estimated useful life.

Plant and machinery-25% on reducing balance
Fixtures and fittings-25% on reducing balance
Computer equipment-33.33% on cost

Investments in associates
Investments in subsidiary and associate undertakings are recognised at cost less impairment.

Stocks
Stocks are stated at the lower of cost and estimated selling price, less costs to complete and sell. Cost includes all costs of purchase, including costs to bring stock to its present location and condition. Provision is made for damaged, obsolete and slow-moving stock where appropriate.

Financial instruments
The company enters into basic financial instruments, which result in the recognition of financial assets and liabilities. Financial instruments are recognised at amortised cost, except for investments in subsidiaries and associate undertakings, which are measured at cost less impairment. At the end of each reporting period financial instruments are assessed for evidence of impairment, and changes are recognised in profit or loss.

Taxation
Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods.

Consideration is given to whether deferred tax should be provided in respect of material timing differences which have not reversed at the balance sheet date. Deferred tax assets are only recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or future taxable profits.

Current tax assets and liabilities are not discounted and are recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

NOTES TO THE FINANCIAL STATEMENTS - continued
For The Year Ended 31 December 2024


2. ACCOUNTING POLICIES - continued

Foreign currencies
Transactions denominated in foreign currencies are translated into sterling and recorded at the rate of exchange ruling at the date of the transaction. Balances at the year-end denominated in a foreign currency are translated into sterling at the rate of exchange ruling at the balance sheet date.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable are charged to the profit and loss in the period to which they relate.

Hire purchase and leasing commitments
Rentals payable under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 18 (2023 - 18 ) .

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 January 2024 111,392
Additions 650
At 31 December 2024 112,042
DEPRECIATION
At 1 January 2024 104,492
Charge for year 2,377
At 31 December 2024 106,869
NET BOOK VALUE
At 31 December 2024 5,173
At 31 December 2023 6,900

5. FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:
Totals
£   
COST
At 1 January 2024
and 31 December 2024 2,040,245
NET BOOK VALUE
At 31 December 2024 2,040,245
At 31 December 2023 2,040,245
Information on loans is as follows:
Totals
£   
At 1 January 2024 1,240,513
Additions 117,074
At 31 December 2024 1,357,587

MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

NOTES TO THE FINANCIAL STATEMENTS - continued
For The Year Ended 31 December 2024


6. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 63,818 77,914
Between one and five years 235,012 240,077
In more than five years 166,467 225,220
465,297 543,211

7. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank overdrafts 99,718 100,876
Debentures 2,669,185 2,669,185
Debenture loan interest 151,712 151,712
2,920,615 2,921,773

A charge over all the undertaking, property and assets of the company was created on 6 December 2011 by Lloyds TSB Bank plc to secure all moneys and liabilities due.

Floating charges have been raised over all the property or undertaking of the company by a director to secure all debenture loan balances and interest due from the company.

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

As at 31 December 2024, a director had loaned the company £2,277,525 (2023 - £2,350,043). The loan attracted interest at 1% over the Bank of England base rate up until 31 December 2013 and the amount due is repayable upon demand. No interest was charged on the loan during the year ended 31 December 2024.

As at 31 December 2024 an amount of £656,435 (2023 - £656,435) was owed to a director with regard to accrued interest charges on his loan account. The amounts due are included within Directors' current accounts and Other creditors due after more than one year.

As at 31 December 2024, a director had debenture loans due from the company of £2,669,185 (2023 - £2,669,185). No interest was charged on the loans during the year ended 31 December 2024.

As at 31 December 2024 an amount of £151,712 (2023 - £151,712) was owed to a director with regard to accrued interest charges on his debenture loans.

The debenture loans due and associated interest charges are repayable upon demand however the director has agreed not to request the secured liabilities for a period of twelve months from the date of approval of the balance sheet in order to support the company's continued operation on a going concern basis. The amounts due are therefore included within Debentures and Other creditors due after more than one year.

MEDSA GROUP LIMITED (REGISTERED NUMBER: 05084053)

NOTES TO THE FINANCIAL STATEMENTS - continued
For The Year Ended 31 December 2024


9. RELATED PARTY DISCLOSURES

During the year ended 31 December 2024, Medsa Group Limited entered into the following transactions with related undertakings:


Outstanding Balance Management Charges
B/Fwd C/Fwd 2023 2024

Maxstim UK 2,309,437 2,098,714 333,000 200,000
Maxstim Europe 6,869 9,986 - -
Greased Lightning 1,240,513 1,357,587 188,000 200,000
Rotafix (Northern) 77,482 81,876 47,500 126,370
Rotafix 400 400 - -
The Magic Molecule Company 89,474 91,185 - -
Greenman Plant Care 67,454 68,066 - -
Contamination Control 62,639 63,917 - -
Medsa Research 18,996 20,240 - -
Heath Research 45,641 9,472 - -
3,918,905 3,801,443 568,500 526,370